 |
EDAP to Present At 19th Annual Wall Street Analyst Forum
About EDAP TMS SA EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound ( HIFU) treatment of localized prostate cancer.
Generex Biotechnology to Present Abstracts at Scientific Symposium
44th Annual Meeting of the European Association for the Study of Diabetes Rome, Italy, September 6- 11, 2008 WORCESTER, Mass., Sept. 5, 2008 ( GLOBE NEWSWIRE)- Generex Biotechnology Corporation ( www.generex. com), the leader in drug delive
Questcor Strengthens Management Team's Manufacturing and Commercial Operations Capabilities
UNION CITY, Calif., Sept. 5, 2008 ( GLOBE NEWSWIRE)- Questcor Pharmaceuticals, Inc. announced today that it has recently expanded its management team with the appointment of Timothy O'Neill, Ph. D., Vice President, Contract Manufacturing, a
57 Start-Up Device Companies Confirmed to Present At Medtech Insight/Windhover Information's 'Invest
Presenting companies to date ( the majority presenting at an In3 event for the first time) from the U.S., Canada, Europe and Israel include Advanced BioSensors, Inc., AugmentRx Medical, Inc., Axogen, Inc., BioLineRx, Ltd., BoneGrafix, Cardi
Alliance for Cancer Gene Therapy Supports Stand Up To Cancer
Cianci also noted that before, during and after the SU2 C telethon, ACGT will be communicating the importance of cancer gene therapy and why it is moving forward as a viable option for treating cancer.
Momenta Pharmaceuticals to Present At the Morgan Stanley Global Healthcare Unplugged Conference
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Momenta Pharmaceuticals to Present At the 3rd Annual Citi Biotech Day
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Generex Biotechnology to Sponsor International Diabetes Symposium in Rome
Opening remarks by Professor Paolo Pozzilli, University Campus Bio-Medico* Epidemiology of Diabetes, the New Epidemic by Dr. Nicola Napoli, University Campus Bio-Medico* New International Diabetes Federation Guidelines on Post-Prandial Gluc
Former Citicorp Corporate Finance Director Appointed to NNRF Board of Advisors
WASHINGTON, Sept. 4, 2008 ( GLOBE NEWSWIRE)- NNRF, Inc. today announced that Steven E. Halliwell, a former Corporate Finance Director for Citibank/Citicorp' s Central and Eastern Europe operations, will join NNRF's Board of Advisors effecti
ZYBRESTAT Named One of the 10 Most Interesting Oncology Projects Available for Partnering by Windhov
ZYBRESTAT is currently being evaluated in a pivotal registration study in anaplastic thyroid cancer ( ATC) under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration ( FDA).
First Biotech Supply Chain Academy to Address Worldwide Business Issues
CONFERENCE HIGHLIGHTS:- ePedigree: Securing The Biotech Supply Chain- Acute to Chronic Care- Necessitating a Paradigm Shift in Healthcare- Biotech Production: Flexibility and Risk Optimization- Regulatory Implications to Global Supply Chain
Zecotek Granted Chinese Patent Rights For LFS Scintillation Material
VANCOUVER, British Columbia, Sept. 3, 2008 ( GLOBE NEWSWIRE)- Zecotek Photonics Inc. today announced that Zecotek Imaging Systems Singapore Pte. Ltd., a wholly-owned subsidiary, has received Notification of Grant of Patent Rights from the C
Chrysalin (Rusalatide Acetate, TP508) Pre-Clinical Results Show Significant Beneficial Effect in Chr
These risks include: delays in obtaining or inability to obtain FDA, institutional review board or other regulatory approvals of pre-clinical or clinical testing; unfavorable outcomes in our pre-clinical and clinical testing; the developmen
MetaPower International, Inc. Announces Capital Restructuring in Order to Further Growth
LAS VEGAS, Sept. 3, 2008 ( GLOBE NEWSWIRE)- MetaPower International, Inc. announced that the Company has implemented a 500 to 1 reverse stock split of its outstanding common stock effective today, dramatically reducing its outstanding share
Avigen Hosts Research Day
PRESENTATIONS* A Strategic Company Overview, by Kenneth Chahine, Ph. D., J.D., President and Chief Executive Officer, Avigen* An Overview of AV650, by Robert Elfont, M.D., Ph. D., Associate Vice President of Clinical Development, Avigen* AV
Discovery Labs' Aerosolized KL-4 Surfactant Selected for Evaluation in Phase 2a Cystic Fibrosis Clin
These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made, including, without limitation, the risks that: Discovery Labs may be unable to re
GeoPharma Announces Second Quarter Earnings Release Date, Annual Meeting, and Research Report Availa
The GeoPharma, Inc. logo is available at http:// www.globenewswire. com/newsroom/ prs/? pkgid = 5384 FORWARD-LOOKING STATEMENTS This press release may contain statements, which constitute forward-looking statements within the meaning of the
Photo Release -- Northrop Grumman's Company-Owned MQ-8B Fire Scout Vertical Unmanned Air System Take
SAN DIEGO, Sept. 2, 2008 ( GLOBE NEWSWIRE)- Northrop Grumman Corporation prepares to move forward with selective demonstrations after conducting the first flight of its company-owned MQ-8B Fire Scout Vertical Unmanned Air System ( VUAS) des
Chelsea Therapeutics Begins Patient Dosing in Second Pivotal Phase III Trial of Droxidopa in Neuroge
CHARLOTTE, N.C., Sept. 2, 2008 ( GLOBE NEWSWIRE)- Chelsea Therapeutics International, Ltd. announced that it has initiated patient dosing in Study 301, the second of two pivotal Phase III trials designed to demonstrate efficacy and support
MorphoSys Announces Publication of First MOR103 Data
MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. http:// hugin. info/130295/ R/1247958/ 270477. pdf CONTACT: MorphoSys AG Dr. Claudia Gutjahr-Loser
MorphoSys to Give Company Presentations At Five Investor Conferences in the U.S. and Europe
Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, will present an overview of the Company at the following conferences: Sal. Oppenheim's 3rd European Healthcare Investors Conference Date: Wednesday, September 3, 2008 Time: 12.20 p
Aastrom Biosciences, Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Encouraging results from two German research groups utilizing Aastrom's proprietary TRC technology platform to manufacture autologous stem cell products were presented at the 2nd Congress of the German Society for Stem Cell Research in Wurz
Harsco Secures $8 Million Infrastructure Contract to Support Victoria Station Work in London
The Harsco Corporation logo is available at http:// www.globenewswire. com/newsroom/ prs/? pkgid = 361 CONTACT: Harsco Corporation Media Contact Kenneth D. Julian 717.730 .3683 kjulian@ harsco. com Investor Contact Eugene M. Truett 717.975
Infinity to Present At Upcoming Conferences
* Adelene Q. Perkins, executive vice present and chief business officer, will present at the 2008 UBS Global Life Sciences Conference in New York on September 25, 2008 at 8: 00 a.m. EDT A live webcast of each of these presentations will be
Generex CEO Interview With Business News Network Available Online
" Power Breakfast" Segment Spotlights Generex Oral-lyn ( tm) Oral Insulin Spray Product Link Available At www.generex. com WORCESTER, Mass., Aug. 28, 2008 ( GLOBE NEWSWIRE)- Generex Biotechnology Corporation ( www.generex. com), the leader
|
|
|
|
|
|
|
|
|
